BioPharma Clinical Trials
Antengene Corporation Limited ("Antengene", SEHK: 6996.HK) , a leading innovative, commercial-stage global biotech company dedicated to discovering, ...
February 26, 2026 | News
etherna, a leading provider of cutting-edge mRNA and lipid nanoparticle (LNP) technology across the biotech and pharma industry, announces that one o...
February 25, 2026 | News
The global race to treat neurodegenerative diseases has reached a new tempo as iRegene Therapeutics pushes its cell therapy pipeline into key clinical...
February 25, 2026 | News
Bioxytran, Inc. (OTCQB: BIXT), a clinical-stage biotechnology company developing breakthrough antiviral treatments, announced it has initiated a research c...
February 24, 2026 | News
Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products...
February 24, 2026 | News
Taiwan-based Formosa Pharmaceuticals ("Formosa", 6838.TW) announced that the company has entered into an exclusive licensing agreement with Arrotex Ph...
February 24, 2026 | News
– Global enrollment continues in the Phase 3 registrational studyfollowing the planned first interim analysis for patients with HPV-negati...
February 24, 2026 | News
Hansa Biopharma AB, ("Hansa" or "the Company"), announced that its Biologics License Application (BLA) for imlifidase has been accepted by the U.S. F...
February 24, 2026 | News
Men have long been waiting for new male contraceptive options outside of just condoms and vasectomy. Non-hormonal methods at the forefront of male interest...
February 23, 2026 | News
Single dose of YOLT-202 led to rapid, robust and dose-dependent increases in AAT levels to normal range Single dose of YOLT-202 was well tolerated with ...
February 23, 2026 | News
Pivotal Phase 3 global KEPLER study of vedolizumab intravenous (IV) in pediatric patients ages 2 to 17, who had an inadequate response to either conven...
February 23, 2026 | News
ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, announced a partnership with Accord Healthcare to provide access to ANKTI...
February 23, 2026 | News
-Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”),&nbs...
February 20, 2026 | News
ANKTIVA plus BCG, with a 71% complete response rate, is the first immunotherapy to receive marketing authorization in Europe for non-muscle invasive blad...
February 20, 2026 | News
Most Read
Bio Jobs
News